Elvitegravir cobicistat emtricitabine tenofovir contraindications: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Elvitegravir cobicistat emtricitabine tenofovir}} {{CMG}}; {{AE}} {{MM}} ==Contraindications== Coadministration of STRIBILD is contraindicated with drugs that ar..." |
No edit summary |
||
| Line 8: | Line 8: | ||
[[File:Stribild table 1.jpg]] | [[File:Stribild table 1.jpg|750px]] | ||
==References== | ==References== | ||
Latest revision as of 17:53, 17 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]
Contraindications
Coadministration of STRIBILD is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. These drugs and other contraindicated drugs (which may lead to reduced efficacy of STRIBILD and possible resistance) are listed in Table 1.[1]
References
Adapted from the FDA Package Insert.